Prime Medicine (PRME)
3.08
+0.13 (4.41%)
Upcoming Events
Latest Headlines
Prime Medicine, Inc. (PRME) Tops Q2 EPS by 12c
August 6, 2026 8:33 AM - StreetInsider
Form 10-Q Prime Medicine, Inc. For: Jun 30
August 6, 2026 8:04 AM - SEC Filing
Form 8-K Prime Medicine, Inc. For: Aug 06
August 6, 2026 8:02 AM - SEC Filing
Prime Medicine Reports Second Quarter 2026 Financial Results and Provides Business Updates
August 6, 2026 8:00 AM - StreetInsider
Prime Drink Group extends private placement, misses filing deadline
July 30, 2026 5:30 PM - StreetInsider
Prime Drink Group Extends Private Placement and Announces Delay in Filing Annual Financial Statements
July 30, 2026 5:30 PM - Globe NewsWire
Prime Medicine gets FDA clearance for Wilson disease gene therapy trial
July 23, 2026 4:05 PM - StreetInsider
Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM577a in H1069Q-mutated Wilson Disease
July 23, 2026 4:05 PM - StreetInsider
H.C. Wainwright Reiterates Buy Rating on Prime Medicine (PRME)
July 10, 2026 6:52 AM - StreetInsider
TD Cowen on Prime Medicine (PRME): 'We continue to view PRME as undervalued for the platform’s potential'
July 8, 2026 12:30 PM - StreetInsider
BofA Securities Comments on Beam Therapeutics Inc (BEAM) Amid Selloff
July 8, 2026 11:32 AM - StreetInsider
Form 8-K Prime Medicine, Inc. For: Jul 06
July 8, 2026 8:02 AM - SEC Filing
Prime Medicine wins arbitration against Beam Therapeutics over PM647
July 8, 2026 8:00 AM - StreetInsider
Prime Medicine Announces Positive Resolution to Arbitration with Beam Therapeutics
July 8, 2026 8:00 AM - StreetInsider
H.C. Wainwright Upgrades Prime Medicine (PRME) to Buy
June 29, 2026 6:03 AM - StreetInsider
FDA grants RMAT designation to Prime Medicine's CGD therapy PM359
June 22, 2026 8:02 AM - StreetInsider
Prime Medicine Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)
June 22, 2026 8:00 AM - StreetInsider
Prime Medicine (PRME) Reiterated at Market Outperform by Citizens as Trial Announced
June 22, 2026 4:16 AM - StreetInsider
Prime Medicine gets New Zealand clearance for Wilson disease gene therapy
June 18, 2026 8:03 AM - StreetInsider
Prime Medicine Announces New Zealand Clearance of Clinical Trial Application for PM577a in H1069Q-mutated Wilson Disease
June 18, 2026 8:00 AM - StreetInsider
Prime Drink Group raises up to $2.2 million in private placement
June 12, 2026 6:30 PM - StreetInsider
Prime Drink Group Announces Private Placement and Agreed Resolution with Creditors
June 12, 2026 6:30 PM - Globe NewsWire
Form 4 Prime Medicine, Inc. For: Jun 05 Filed by: Schenkein David P
June 8, 2026 4:21 PM - SEC Filing
Form 4 Prime Medicine, Inc. For: Jun 05 Filed by: Marrazzo Jeffrey D
June 8, 2026 4:20 PM - SEC Filing
Form 4 Prime Medicine, Inc. For: Jun 05 Filed by: NELSEN ROBERT
June 8, 2026 4:19 PM - SEC Filing
Form 4 Prime Medicine, Inc. For: Jun 05 Filed by: Kelly Michael Aaron
June 8, 2026 4:18 PM - SEC Filing
Form 4 Prime Medicine, Inc. For: Jun 05 Filed by: Foster-Cheek Kaye I
June 8, 2026 4:17 PM - SEC Filing
Form 4 Prime Medicine, Inc. For: Jun 05 Filed by: Chung Wendy
June 8, 2026 4:15 PM - SEC Filing
Form 4 Prime Medicine, Inc. For: Jun 05 Filed by: Cahill Thomas
June 8, 2026 4:13 PM - SEC Filing
Form 8-K Prime Medicine, Inc. For: Jun 05
June 8, 2026 4:11 PM - SEC Filing
Prime Medicine to Present at Goldman Sachs 47th Annual Global Healthcare Conference
June 3, 2026 8:00 AM - StreetInsider
Prime Medicine to Present at Jefferies Global Healthcare Conference
May 28, 2026 8:00 AM - StreetInsider
Full Article List
